TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00212576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Blocks Project
Description: This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
Study: NCT01594450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological mesh
Description: patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without biological mesh
Description: patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
Study: NCT02505490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Television
Description: The purpose is to determine whether television impacts liking of food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Television
Description: The purpose is to determine whether the lack of television impacts liking of food.
Study: NCT04481178

Intervention type: OTHER
Intervention: Laser (QS, Picosecond laser)
Description: QS-Nd Yag Laser, Picosecond laser
Study: NCT00100802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT01530373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral solifenacin 5.0 mg daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: oral clonidine 0.1 mg daily for 3 weeks
Study: NCT03384238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: Given IV
Study: NCT04537403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)
Description: Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
Study: NCT02444858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group(Normal saline)
Description: Normal saline in same volume as MSCs are transplanted to patients.
Study: NCT05799742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral hernioplasty
Study: NCT02492087

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline 0.9%
Description: Sterile Normal saline 0.9% 120mls solution
Study: NCT04031053

Intervention type: OTHER
Intervention: Pharmacokinetic study
Description: The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose

Intervention type: OTHER
Intervention: Pharmacokinetic study
Description: The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
Study: NCT02586077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study: NCT03807076

Intervention type: OTHER
Group type: OTHER
Intervention: GIP-A
Description: GIP-A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03853512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to the other side of the inguinal region.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to the other side of the inguinal region.
Study: NCT04077229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: Text Message Intervention
Description: Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
Study: NCT01059396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: GPVH ≥ 10 mmHg - responders: propranolol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: GPVH ≥ 10 mmHg nonresponders: carvedilol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo propranolol / carvedilol
Study: NCT02366741

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole brain radiotherapy with reduced dose to the hippocampi
Description: VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
Study: NCT01478152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-like Medical Device: Ectoin Inhalation Solution
Description: After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose.
Study: NCT00599027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray once daily (two puffs per nostril) in the morning.
Study: NCT04250012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT intervention
Description: The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
Study: NCT00750165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series CPAP Humidifier
Description: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
Study: NCT02140203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Training
Description: one-year experimental training (three times per week and one hour per session)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Training
Description: one-year experimental training (three times per week and one hour per session)
Study: NCT03116308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone (OPC)
Description: 50 mg OPC capsules; oral route
Study: NCT03329417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented training
Description: Motor training targeted to goals that are relevant to the functional needs of the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented training
Description: Motor training targeted to goals that are relevant to the functional needs of the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-oriented training
Description: Motor training targeted to goals that are relevant to the functional needs of the patient
Study: NCT03627494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT00726154

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IPSRT
Description: Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care
Description: The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
Study: NCT02218619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid (TUDCA)
Description: TUDCA at 1750 mg/day x 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: Placebo
Study: NCT01753336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
Study: NCT04205370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Pregnancy Coach
Description: Naturalistic monitoring of their typical sleep patterns and behaviors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Pregnancy Coach
Description: The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
Study: NCT00669071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%
Description: Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® Moisturizing Cream as Inactive Control
Description: Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Study: NCT03014336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: memsorb
Description: memsorb is a CO2 filter replacing current chemical CO2 absorbers
Study: NCT00539357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Description: Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
Study: NCT02219971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Study: NCT04375865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2111
Description: celecoxib 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2112
Description: Tramadol 150mg
Study: NCT03692143

Intervention type: DRUG
Intervention: Teriparatide
Description: subcutaneous injection of teriparatide(20 mg) once daily
Study: NCT03309982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant polyphenol blend
Description: A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
Study: NCT04593550

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: BEHAVIORAL
Intervention: BrainCheck Cognitive Assessment
Description: Undergo cognitive function assessment BrainCheck

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Undergo 3D-Confusion assessment

Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Undergo EEG
Study: NCT02558101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control invitation materials
Description: In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention invitation materials
Description: The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
Study: NCT03445767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedSafer
Description: An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.